Fibrocell Science Inc

Fibrocell Science — Investor Presentation (October 2012)

31 slides from Fibrocell Science's investor presentation, Oct 18, 2012

  1. Slide 1: Fibrocell Investor Presentation, October 17, 2012

    t FIBROCELL . October 17,2012 —$__

  2. Slide 2: Forward Looking Statement

    2 Forward Looking Statement This presentation includes statements that are "forward-looking statements." While management has based any forward-looking statements contained in the presentation on its current expectations, the information on which such expectations were based may change. These forwar

  3. Slide 3: Agenda

    3 FCSC Overview Transformative Raise Intrexon Collaboration Use of Proceeds Pipeline Overview Milestones - Looking Forward Agenda

  4. Slide 4: Company Overview

    4 Unique autologous fibroblast therapy company with revenue growth opportunities and a broad platform Fibroblast cells produce collagen and elastin Fibroblast cells decrease with age leading to a breakdown in connective tissue fibers, collagen matrix and skin structure Stem cell platform derived fro

  5. Slide 5: Transaction Overview

    Transaction Overview Financial overview $45mm private capital raise in a common stock transaction at $0.10 per share of 450mm shares Investor syndicate was led by a Third Security, LLC affiliated fund Third Security is a venture capital company led by Randal J. Kirk Strong group of institutional and

  6. Slide 6: Intrexon Collaboration

    Intrexon Collaboration Overview of strategic collaboration with Intrexon Concurrent with the transaction, Fibrocell entered into a strategic collaboration with Intrexon Corporation Intrexon is a private synthetic biology company that utilizes its proprietary technologies to provide control over cell

  7. Slide 7: Intrexon Collaboration: Main goals

    Development and commercialization of the next generation of genetically modified and non-genetically modified autologous fibroblasts UltraVector(r), DNA and RNA MOD engineering, protein engineering, transcription control chemistry and genome engineering Improve COGS through cell system engineering E

  8. Slide 8: Unlocking the power of the fibroblast

    Regenerative Medicine Burn Scars, Acne Scars, Vocal Cord Scarring, Periodontal, Wound Healing Exponential Growth Potential Expansion beyond aesthetic indications Regenerative medicine and stem cell therapy High unmet medical needs beyond aesthetics Potential to generate 2nd generation fibroblast pro

  9. Slide 9: Expansion into Larger Markets

    Aesthetics Regenerative Medicine Stem Cell Therapy Stem cells differentiate into other useful cell types (e.g. bone cells and cartilage), opening the door to groundbreaking targeted therapies 45,000 people hospitalized each year with severe burns (1) ~176,778 - 589,260 patients with vocal cord scarr

  10. Slide 10: Use of Proceeds From Recent Financing

    Expand clinical development of fibroblasts - for example, restrictive burn scars, acne scars, and vocal cord scars Increase manufacturing capacity and implement process improvements to reduce COGS Develop autologous GM-fibroblast and dermal products under the Intrexon ECC Advance stem cell research

  11. Slide 11: LAVIV Aesthetic Overview

    LAVIV(r) Aesthetic Overview 11

  12. Slide 12: Market Overview for Cosmetic Procedures

    12 Any discrepancies in percentage change are due to procedures performed in 1997 that are no longer performed in 2011. na = Rankings for this procedure in prior years are not available. Source: American Society for Aesthetic Plastic Surgery. Market Overview for Cosmetic Procedures Growing market fo

  13. Slide 13: LAVIV Aesthetic Opportunity

    13 LAVIV(r) is the first and only personalized aesthetic cell therapy for the treatment of nasolabial fold wrinkles Fibroblasts generate collagen Attractive to younger demographics who: Are not satisfied with current treatment options Are attracted to organic products Seek a complement to existing p

  14. Slide 14: LAVIV - Media

    14 LAVIV(r) - Media Successful media outreach LAVIV(r) has been featured in nearly 100 business and trade publications, 100 consumer placements (online and print), 12 national beauty magazines, 16 major beauty websites and blogs, nearly 150 TV and radio segments, an exclusive NBC segment that aired

  15. Slide 15: LAVIV Awards & Recognition

    15 Fibrocell Science - LAVIV(r) Awards & Recognition . Fibrocell named runner-up in prestigious Wall Street Journal Technology Innovations Awards, Medicine and Biotechnology category, October 2012 Golden Bridge Award: Beauty, Lifestyle and Fashion Innovations, September 2012 The June 2011 FDA approv

  16. Slide 16: Fibroblast Pipeline

    Fibroblast Pipeline 16

  17. Slide 17: Product Pipeline Status

    Product Pipeline 17 Status Aesthetic (Nasolabial Lines and Other) Approved by the FDA in June 2011 for moderate to severe nasolabial fold wrinkles Acne Scarring In end of phase II discussions with the FDA and evaluating a path forward Restrictive Burn Scars Submitted Phase II study protocol to the F

  18. Slide 18: Overview of Acne Scarring

    18 Acne scarring is the permanent discoloration and/or indentation of the skin as a result of moderate to severe acne scars Opportunity to capture market share No medical treatments for acne scars 20 million Americans have acne badly enough to cause scars (2) Completed one Phase II study Statistical

  19. Slide 19: Acne Scarring Phase II Study Results

    19 Randomized, multi-center, double-blind, placebo-controlled study in patients with moderate to severe acne scars 99 subjects received three injections in one cheek and vehicle control (cell culture media) in the other at 14 day intervals Patients evaluated up to four months after the last treatmen

  20. Slide 20: Acne Scarring Follow-Up Photos

    20 Acne Scarring Follow-Up Photos from Study 25 month photos demonstrate potential long-lasting effect Time

  21. Slide 21: Restrictive Burn Scars

    Autologous fibroblast cell therapy offers functional and aesthetic improvements for burn scar victims Restrictive burn scars are a potential blockbuster indication 45,000 yearly hospitalizations for severe burns (2) Open-label case study for autologous fibroblast therapy in the management of burn sc

  22. Slide 22: High Unmet Medical Need Areas: Burn Scars

    22 High Unmet Medical Need Areas Case studies: burn/burn scars Burn / Burn Scars Note: Photos from LAVIV prescribers. Not from clinical studies. Case 1 Case 2

  23. Slide 23: High Unmet Medical Need Areas: Burn Scars

    23 High Unmet Medical Need Areas Case study: burn/burn scars Burn / Burn Scars Before 5 Weeks Post Injury 7 Months Post Injury 18 Months Post Injury Area Treated with LAVIV Note: Photos from LAVIV (r)prescribers. Not from clinical studies.

  24. Slide 24: High Unmet Medical Need Areas: Injury induced scarring

    24 (1) Iraqi war veteran who sustained injuries as a result of shrapnel. Note: Photos from LAVIV(r) prescribers. Not from clinical studies. High Unmet Medical Need Areas Case Study: Injury induced scarring

  25. Slide 25: Vocal Cord Scarring

    25 Vocal cord trauma is the most commonly encountered finding in dysphonia (loss of voice) Most often seen after surgery on the vocal folds but can also result from radiation therapy, vocal cord trauma, and idiopathic causes Currently has no effective therapy Positive results in pilot studies Autolo

  26. Slide 26: Stem Cell Program with UCLA and MIT

    26 Fibrocell has discovered and purified a subset of Mesenchymal stem cells (MSCs) that can differentiate into other potentially useful cell-types, such as cells that form bone and cartilage The cells can be used for either in vitro research applications or re-implantation back into the donor Since

  27. Slide 27: bo < = P= is) £ < oO =

    bo < = 3 P= is) £ 5 < oO =

  28. Slide 28: Regulatory Pathway and Expansion Plan

    Regulatory Pathway and Expansion Plan Targeted Capacity of 3K in 2013, 8K-10K in 2014 and 12K in 2015 Submitted briefing package to FDA detailing plan to increase capacity FDA provided feedback and agreed with regulatory pathway Capacity increase will occur in stages over time: Biopsies Received per

  29. Slide 29: Process Development Projects

    Rapid test methods Evaluating alternative growth surface systems Expanding shipper capacity and reuse Reduction in enzyme volume Test requirement reduction Automated cell expansion system Development of an alternative growth media Process Development Projects 29

  30. Slide 30: Milestones 2012 - 2014

    Milestones 2012 - 2014 30

  31. Slide 31: Milestones 2012 - 2014

    Milestones 2012 - 2014 2012 2014 2013 Acne Scar Publication Initiation of Manufacturing Capacity Expansion Initiation of Personalized Cream Clinical Study. Pilot Launch of Personalized Cream Initiate Animal Studies Using MSC Cells Derived From Skin Initiate VCS program Initiation of Acne Scar Progra

Fibrocell Science — Investor Presentation (October 2012) on 6ix